PL3761982T3 - Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych - Google Patents

Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych

Info

Publication number
PL3761982T3
PL3761982T3 PL19765122.7T PL19765122T PL3761982T3 PL 3761982 T3 PL3761982 T3 PL 3761982T3 PL 19765122 T PL19765122 T PL 19765122T PL 3761982 T3 PL3761982 T3 PL 3761982T3
Authority
PL
Poland
Prior art keywords
nalfurafine
treatment
demyelinating diseases
demyelinating
diseases
Prior art date
Application number
PL19765122.7T
Other languages
English (en)
Inventor
Bronwyn Maree Kivell
Anne Camille La Flamme
Thomas Edward Prisinzano
Original Assignee
Victoria Link Ltd
University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900754A external-priority patent/AU2018900754A0/en
Application filed by Victoria Link Ltd, University Of Kansas filed Critical Victoria Link Ltd
Publication of PL3761982T3 publication Critical patent/PL3761982T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19765122.7T 2018-03-08 2019-03-07 Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych PL3761982T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018900754A AU2018900754A0 (en) 2018-03-08 Treatment of demyelinating diseases
PCT/IB2019/051870 WO2019171333A1 (en) 2018-03-08 2019-03-07 Treatment of demyelinating diseases

Publications (1)

Publication Number Publication Date
PL3761982T3 true PL3761982T3 (pl) 2025-03-17

Family

ID=67846938

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19765122.7T PL3761982T3 (pl) 2018-03-08 2019-03-07 Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych

Country Status (11)

Country Link
US (3) US20210015813A1 (pl)
EP (1) EP3761982B1 (pl)
AU (1) AU2019229892B2 (pl)
CA (1) CA3091752A1 (pl)
DK (1) DK3761982T3 (pl)
ES (1) ES3006014T3 (pl)
FI (1) FI3761982T3 (pl)
HU (1) HUE069820T2 (pl)
PL (1) PL3761982T3 (pl)
PT (1) PT3761982T (pl)
WO (1) WO2019171333A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3761982T3 (da) 2018-03-08 2025-01-02 Victoria Link Ltd Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme
AU2021238781A1 (en) * 2020-03-20 2022-10-06 Medizinische Universität Wien Cyclotides in combination with kappa opioid receptor ligands for MS therapy
WO2024229174A1 (en) * 2023-05-02 2024-11-07 Cognito Therapeutics, Inc. Gamma stimulation and neuromodulator combination therapy
WO2025255116A1 (en) * 2024-06-03 2025-12-11 The Cleveland Clinic Foundation Methods of treatment for opioid-induced ventilatory depression and muscle rigidity

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994466A (en) 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
ES2197953T3 (es) 1995-09-26 2004-01-16 Toray Industries, Inc. Derivados de indol y aplicaciones medicas de los mismos.
DE69732868T2 (de) 1996-11-25 2006-04-13 Toray Industries, Inc. Mittel gegen Juckreiz
US6440987B1 (en) 1996-11-25 2002-08-27 Toray Industries, Inc. Antipruritic
PT948965E (pt) 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
JP2000053572A (ja) 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
CN1204139C (zh) 1999-08-24 2005-06-01 东丽株式会社 神经性疼痛治疗剂
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
JP4370683B2 (ja) 2000-05-08 2009-11-25 東レ株式会社 そう痒疾患の検査方法
AU2408602A (en) 2000-11-22 2002-06-03 Toray Industries Indole derivatives and use thereof in medicines
US8338442B2 (en) 2001-03-30 2012-12-25 Toray Industries, Inc. Remedies for psychoneurosis
JP2002332284A (ja) 2001-05-08 2002-11-22 Toray Ind Inc 二価性モルヒナン誘導体およびその医薬用途
JP4957489B2 (ja) 2002-10-09 2012-06-20 東レ株式会社 含窒素環状置換基を有するモルヒナン誘導体またはその薬理学的に許容される酸付加塩を含有する医薬
BR0314754A (pt) 2002-10-09 2005-07-26 Toray Industries Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica
TW200533355A (en) 2004-03-30 2005-10-16 Toray Industries Antipruritic agent
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
PE20060723A1 (es) 2004-11-04 2006-08-29 Toray Industries Derivados de morfina como agentes analgesicos
AU2006221314B2 (en) 2005-03-10 2012-09-06 Toray Industries, Inc. Antipruritic agent for pruritus caused by multiple sclerosis
WO2006109671A1 (ja) 2005-04-06 2006-10-19 Toray Industries, Inc. モルヒナン誘導体の結晶及びその製造法
WO2007055184A1 (ja) 2005-11-09 2007-05-18 Toray Industries, Inc. 機能性腸障害の治療または予防剤
WO2007072749A1 (ja) 2005-12-21 2007-06-28 Toray Industries, Inc. 鎮咳剤
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
PL2151240T3 (pl) 2007-04-24 2014-01-31 Toray Industries Środek terapeutyczny lub profilaktyczny przeciw dyskinezie
PT2151241E (pt) 2007-04-26 2012-05-07 Toray Industries Preparação sólida estável compreendendo um derivado de 4,5-epoximorfinano
PL2196206T3 (pl) 2007-10-05 2020-02-28 Toray Industries, Inc. Środek do łagodzenia problemów skórnych zawierający pochodną morfinanu lub jego farmakologicznie dopuszczalną kwasową sól addycyjną jako substancję czynną
JP5252391B2 (ja) 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
CA2740476C (en) 2008-10-24 2016-04-05 Toray Industries, Inc. Stable tablet containing 4,5-epoxymorphinan derivative
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
JP2011074018A (ja) 2009-09-30 2011-04-14 Toray Ind Inc 線維筋痛症の治療剤又は予防剤
PH12012501552A1 (en) 2010-01-29 2017-04-26 Toray Industries Therapeutic or prophylactic agent for biliary diseases
CA2825165C (en) 2011-01-31 2018-07-03 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EP2806948B1 (en) 2012-01-27 2020-01-15 New York University Method for enhancing remyelination using gli1 inhibitors
US20150150935A1 (en) 2012-06-05 2015-06-04 Cara Therapeutics, Inc. Peripheral kappa receptor agonists for reducing pain and inflammation
CN102993125A (zh) 2012-09-25 2013-03-27 中国人民解放军第四军医大学 一种新的用于缺血心脏保护作用的κ-阿片受体激动剂
WO2014100199A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Micropillar arrays for assaying myelination
WO2015025767A1 (ja) 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
WO2015025766A1 (ja) 2013-08-21 2015-02-26 久光製薬株式会社 貼付剤
JP6247118B2 (ja) 2014-03-05 2017-12-13 東海カプセル株式会社 カプセル充填組成物
JP2016155794A (ja) 2014-06-09 2016-09-01 富士カプセル株式会社 ナルフラフィン塩酸塩及びフィチン酸又はその塩を含有するカプセル製剤
CN105462930B (zh) 2014-06-24 2020-10-20 中国人民解放军军事医学科学院毒物药物研究所 一种筛选κ阿片受体激动剂的细胞模型及筛选方法
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
JPWO2016208729A1 (ja) 2015-06-24 2018-04-12 国立大学法人 筑波大学 ナルフラフィン含有経皮吸収貼付剤
AU2016324317A1 (en) 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
JPWO2017094337A1 (ja) 2015-12-04 2018-09-20 ニチバン株式会社 貼付剤
WO2017170933A1 (ja) 2016-03-31 2017-10-05 ニチバン株式会社 貼付剤製品
WO2017220431A1 (en) 2016-06-20 2017-12-28 Almirall, S.A. Fused pyrazole derivatives as jak inhibitors
JP2018048093A (ja) 2016-09-23 2018-03-29 東レ株式会社 モルヒナン誘導体及びその医薬用途
ES2902123T3 (es) 2017-03-31 2022-03-25 Toray Industries Composición medicinal en tabletas que comprende nalfurafina
DK3761982T3 (da) 2018-03-08 2025-01-02 Victoria Link Ltd Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme
EP3761981A4 (en) 2018-03-08 2021-12-15 Victoria Link Ltd TREATMENT OF DEMYELINIZING DISEASES

Also Published As

Publication number Publication date
US20210069179A1 (en) 2021-03-11
US11324742B2 (en) 2022-05-10
EP3761982B1 (en) 2024-10-09
EP3761982A4 (en) 2021-12-15
AU2019229892B2 (en) 2025-01-30
AU2019229892A1 (en) 2020-09-03
PT3761982T (pt) 2024-12-30
DK3761982T3 (da) 2025-01-02
EP3761982A1 (en) 2021-01-13
HUE069820T2 (hu) 2025-04-28
WO2019171333A1 (en) 2019-09-12
CA3091752A1 (en) 2019-09-12
US12318380B2 (en) 2025-06-03
RU2020128028A (ru) 2022-04-08
US20210015813A1 (en) 2021-01-21
FI3761982T3 (fi) 2025-01-03
US20230096920A1 (en) 2023-03-30
ES3006014T3 (en) 2025-03-17

Similar Documents

Publication Publication Date Title
IL276398A (en) Combined treatment for mastocytosis
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
IL279260A (en) KDM1A inhibitors for the treatment of diseases
SG11202006374VA (en) Treatment of demyelinating diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
IL283948A (en) Methods for treating depression
IL282643A (en) Soft combinations for the treatment of hematological diseases
IL276482A (en) Compounds for pain management
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3744347A4 (en) COMPOSITION FOR USE IN THE TREATMENT OF SKIN DISEASES
PL3603621T3 (pl) Liposomy do leczenia chorób oczu
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL282361A (en) Treatment for neurological diseases
PL3761982T3 (pl) Zastosowanie nalfurafiny w leczeniu chorób demielinizacyjnych
LT3924340T (lt) Indazolil-izoksazolo dariniai, skirti ligų, tokių kaip vėžys, gydymui
IL284162A (en) Integrated healing for cancer treatment
PT3619204T (pt) Compostos para o tratamento de doenças respiratórias
IL281782A (en) Drug combination for cancer treatment
HK40061035A (en) Novel compounds for the treatment of respiratory diseases
AU2018904241A0 (en) Novel compounds for the treatment of respiratory diseases
AU2018900754A0 (en) Treatment of demyelinating diseases
AU2018900753A0 (en) Treatment of demyelinating diseases
GB201909438D0 (en) Treatment of diseases
AU2017901647A0 (en) Compounds for the treatment of respiratory diseases